Celgene teams up with TriNetX for ‘next-gen’ drug trial design

Celgene logo

Clinical research network linker TriNetX has signed a new collab with cancer biotech Celgene ($CELG) to help with its clinical trial design and research for the company’s next-generation drug programs.

Under the deal, Celgene will gain real time access to medical data from electronic medical records through TriNetX’ network of healthcare institutions to support: clinical study and protocol design, site selection, and patient recruitment across a range of therapeutic areas and development stages.

TriNetX--which works as a clinical data network of healthcare providers, pharma/biotech companies and CROs--said its system can use a data point that can be traced to healthcare providers who have the ability to identify individual patients, allowing clinical researchers to develop virtual patient cohorts that can be recapitulated in real world clinical trial settings.

“TriNetX represents the future of a data-driven approach to clinical trial design and research,” said Jay Kaminski, SVP, global clinical research development and operations at Celgene. “This collaboration is an important part of the innovations we have been making at Celgene to realize the power of data analytics within our clinical research organization.”

Gadi Lachman, CEO at TriNetX, said: “Our mission is to disrupt the clinical trial design space by unleashing the power of data that is currently locked away.

“Through our network, healthcare providers, pharma and contract research organizations can create strategic partnerships to improve clinical research and patient care, and we are honored to have Celgene as part of our network. We see this collaboration as a win-win for Celgene, TriNetX, our member institutions, and ultimately patients.”

This builds on the deal TriNetX struck with Novartis ($NVS) back in March for a similar collab set-up. No financial details of either deal have been released.

-check out the statement